Patent US4495042A successfully refreshed from Google Patents.
Patent US4882142A successfully refreshed from Google Patents.
US4882142A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Bone marrow suppressing agents
Assignee: Dow Chemical Co
•
Filing: 1988-12-19
•
Granted: 1989-11-21
•
Expires: 2008-12-19
Abstract
Abstract The invention concerns a method for suppressing bone marrow which comprises administering to a mammal at least one bone marrow suppressing complex of a radionuclide selected from the group consisting of Samarium-153, Gadolinium-159, and Holmium-166 and 1,4,7,10-tetraazacyclododecanetetramethylenephosphonic acid a physiologically acceptable salt thereof. Suitable compositions for use in this method are also provided.
Inventors
- 👤 Jaime Simon
- 👤 Joseph R. Garlich
- 👤 David A. Wilson
- 👤 Kenneth McMillan
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-04 18:28
CPC Classifications
A; A61; A61K; A61K51/00; A61K51/02; A61K51/04; A61K51/0489; A61K51/0474; A61K51/0482; A61P; A61P7/00; A61K2121/00
Claims Analysis
Total Claims: 32
Claim 1
Independent Claim
56 words
A method for suppressing bone marrow which comprises administering to a mammal in need of such treatment a bone marrow suppressing amount of at least one bone marrow suppressing composition comprising at least one radionuclide selected from the group consisting of Samarium-153, Gadolinium-159, and Holmium-166 complexed with 1,4,7, 10-tetraazacyclododecanetetramethylenephosphonic acid or a physiologically acceptable salt thereof.
Claim 2
Independent Claim
56 words
A method for suppressing bone marrow which comprises administering to a mammal in need of such treatment a bone marrow suppressing amount of at least one bone marrow suppressing composition comprising at least one radionuclide selected from the group consisting of Samarium-153, Gadolinium-159, and Holmium-166 complexed with 1,4,7, 10-tetraazacyclododecanetetramethylenephosphonic acid or a physiologically acceptable salt thereof.
Claim 3
Dependent Claim
10 words
The method of claim 1 wherein the radionuclide is Samarium-153.
Claim 4
Dependent Claim
10 words
The method of claim 1 wherein the radionuclide is Gadolinium-159.
Claim 5
Dependent Claim
10 words
The method of claim 1 wherein the radionuclide is Holmium-166.
Claim 6
Dependent Claim
43 words
The method of claim 1 used in conjunction with an additional treatment regimen using at least one of (a) one or more bone marrow suppressing agents, and/or (b) one or more chemotherapeutic agents, and/or (c) one or more radiotherapeutic agents or radiotherapeutic methods.
Claim 7
Dependent Claim
16 words
The method of claim 1 used in conjunction with total body irradiation or targeted external irradiation.
Claim 8
Dependent Claim
20 words
The method of claim 1 including the additional step of bone marrow transplantation after sufficient bone marrow suppression is achieved.
Claim 9
Dependent Claim
24 words
The method of claim 1 used in conjunction with one or more therapeutic regimens for the treatment of leukemia, lymphoma, myeloma or Hodgkin's disease.
Claim 10
Dependent Claim
13 words
The method of claim 8 wherein the disease being treated is a leukemia.
Claim 11
Dependent Claim
13 words
The method of claim 8 wherein the disease being treated is a lymphoma.
Claim 12
Dependent Claim
13 words
The method of claim 8 wherein the disease being treated is a myeloma.
Claim 13
Dependent Claim
13 words
The method of claim 8 wherein the disease being treated is Hodgkin's disease.
Claim 14
Dependent Claim
17 words
The method of claim 1 used in conjunction with a treatment employing at least one chemotherapeutic agent.
Claim 15
Dependent Claim
21 words
The method of claim 13 wherein the chemotherapeutic agent is selected from dimethyl busulfan, cyclophosphamide, bischloroethyl nitrosourea, cytosine arabinoside, and 6-thioguanine.
Claim 16
Dependent Claim
22 words
The method of claim 1 used in conjunction with total body irradiation and with a treatment employing at least one chemotherapeutic agent.
Claim 17
Dependent Claim
21 words
The method of claim 15 wherein the chemotherapeutic agent is selected from dimethyl busulfan, cyclophosphamide, bischloroethyl nitrosourea, cytosine arabinoside, and 6-thioguanine.
Claim 18
Dependent Claim
64 words
A sterile composition suitable for administration to a mammal suppressing bone marrow comprising at least one radionuclide selected from the group consisting of Samarium-153, Gadolinium-159, and Holmium-166 complexed with 1,4,7,10-tetraazacyclododecanetetramethylenephosphonic acid or a physiologically-acceptable salt thereof and wherein the radionuclide in dosage form is present in an amount containing from about 18 to about 1850 megabecquerels per kilogram of body weight of said mammal.
Claim 19
Dependent Claim
64 words
A sterile composition suitable for administration to a mammal suppressing bone marrow comprising at least one radionuclide selected from the group consisting of Samarium-153, Gadolinium-159, and Holmium-166 complexed with 1,4,7,10-tetraazacyclododecanetetramethylenephosphonic acid or a physiologically-acceptable salt thereof and wherein the radionuclide in dosage form is present in an amount containing from about 18 to about 1850 megabecquerels per kilogram of body weight of said mammal.
Claim 20
Dependent Claim
16 words
The composition of claim 17 wherein the ligand to radionuclide ratio is from 1:1 to 2:1.
Claim 21
Dependent Claim
25 words
The composition of claim 17 wherein the dosage form contains from about 185 to about 1850 mega-becquerels per kilogram of body weight of said mammal.
Claim 22
Dependent Claim
12 words
The composition of claim 19 wherein the macrocyclic ligand is 1,4,7,10-tetraazacyclododecanetetramethylenephosphonic acid.
Claim 23
Dependent Claim
10 words
The composition of claim 20 wherein the radionuclide is Sm-153.
Claim 24
Dependent Claim
10 words
The composition of claim 20 wherein the radionuclide is Ho-166.
Claim 25
Dependent Claim
10 words
The composition of claim 20 wherein the radionuclide is Gd-159.
Claim 26
Dependent Claim
10 words
The composition of claim 17 wherein the radionuclide is Sm-153.
Claim 27
Dependent Claim
10 words
The composition of claim 17 wherein the radionuclide is Ho-166.
Claim 28
Dependent Claim
10 words
The composition of claim 17 wherein the radionuclide is Gd-159.
Claim 29
Dependent Claim
14 words
A pharmaceutical formulation comprising the composition of claim 17 in a pharmaceutically acceptable carrier.
Claim 30
Dependent Claim
10 words
The composition of claim 27 wherein the radionuclide is Sm-153.
Claim 31
Dependent Claim
10 words
The composition of claim 27 wherein the radionuclide is Ho-166.
Claim 32
Dependent Claim
10 words
The composition of claim 27 wherein the radionuclide is Gd-159.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-11-20 | 1993-05-22 | 1993-11-21 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-11-20 | 1997-05-22 | 1997-11-21 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-11-20 | 2001-05-22 | 2001-11-21 | $7700.00 | Window Closed / Lapsed |